|PUBLICATIONS (Ranked by impact factor of the journal)|
T Cell Repertoire following Autologous Stem Cell Transplantation for Multiple Sclerosis|
In a Phase II study of hematopoietic stem cell transplantation (HSCT) for poor-prognosis multiple sclerosis, scientists used high-throughput deep TCRß chain sequencing to assess millions of individual TCRs per patient sample. They found that HSCT has distinctive effects on CD4+ and CD8+ T cell repertoires. [J Clin Invest]
Full Article | Press Release
Regulatory T Cells in Rheumatoid Arthritis Showed Increased Plasticity toward Th17 but Retained Suppressive Function in Peripheral Blood
Scientists investigated IL-17-producing regulatory T cells from patients with rheumatoid arthritis, and characterized their regulatory capacity and clinical significance. [Ann Rheum Dis]
Hypoxia and STAT3 Signaling Interactions Regulate Pro-Inflammatory Pathways in Rheumatoid Arthritis
Researchers examined the effect of hypoxia on Signal Transducer and Activator of Transcription 3 (STAT3)-induced pro-inflammatory pathways in rheumatoid arthritis. [Ann Rheum Dis]
Differential Effects of Fingolimod on B-Cell Populations in Multiple Sclerosis
Scientists analyzed blood samples from nine fingolimod-treated and 19 control patients with multiple sclerosis by flow cytometry, to determine the frequencies and activation states of naive B cells, memory B cells, and plasmablasts. The frequencies of each B-cell population in peripheral blood mononuclear cells were greatly reduced two weeks after starting fingolimod treatment. [Mult Scler]
TIRC7 and HLA-DR Axis Contributes to Inflammation in Multiple Sclerosis
TIRC7 was expressed in brain-infiltrating lymphocytes and strongly correlated with disease activity in multiple sclerosis (MS). TIRC7 expression was reduced in T cells and induced in B cells in peripheral blood lymphocytes obtained from MS patients. [Mult Scler]
ImmTAC-Redirected Tumor Cell Killing Induces and Potentiates Antigen Cross-Presentation by Dendritic Cells
Using an ImmTAC (immune-mobilizing monoclonal T cell receptor against cancer) specific for a HLA-A*02-restricted peptide derived from the melanoma antigen gp100, scientists observed that ImmTAC-driven melanoma-cell death leads to cross-presentation of melanoma antigens by dendritic cells. [Cancer Immunol Immunother]
Bufalin, a Bioactive Component of the Chinese Medicine Chansu, Inhibits Inflammation and Invasion of Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Researchers investigated the effects of bufalin on tumor necrosis factor-alpha (TNF-a)-induced invasion of rheumatoid arthritis fibroblast-like synoviocytes. Their results revealed that TNF-a significantly increased p65 translocation into nucleus and enhanced nuclear factor-kappa B DNA-binding activity, which were dose-dependently inhibited by bufalin. [Inflammation]
Increased TTS Expression in Patients with Rheumatoid Arthritis
Scientists studied the imbalance expressions of indoleamine 2,3-dioxygenase (IDO) and tryptophanyl-tRNA synthetase (TTS) with rheumatoid arthritis patients. The expressions of IDO and TTS were analyzed by real-time quantitative polymerase chain reaction and flow cytometry in peripheral blood mononuclear cells. [Clin Exp Med]
Win a $25 Amazon Gift Card!
Connexon Creative is evaluating reader interest in a new social media platform. Fill out this quick survey for your chance to win 1 of 4 $25 gift cards! Take survey here
|Subscribe to our sister publications: Immunology of Infectious Disease News
and Immune Regulation News!|
A*STAR, NUS and NUH Join Forces to Understand Immune Erosion in Elderly|
A*STAR’s Singapore Immunology Network signed a three-year partnership with the National University of Singapore (NUS), National University Hospital (NUH) and Sanofi Pasteur to embark on a Phase IV clinical trial to understand age-related loss of immunity, known as immunosenescence, in elderly. [A*STAR]
Aurigene Discovery Technologies Limited and Pierre Fabre Announce a Licensing Agreement for a New Cancer Therapeutic in Immuno-Oncology: AUNP12, an Immune Checkpoint Modulator Targeting the PD-1 Pathway
Pierre Fabre and Aurigene announced that the two companies have entered into a collaborative license, development and commercialization agreement granting Pierre Fabre global Worldwide rights (excluding India) to a new immune checkpoint modulator, AUNP-12. [Aurigene Discovery Technologies Limited]
DiaVacs Announces a Strategic Collaboration with Profil Institute to Conduct Phase IB/IIA Randomized Clinical Trial of New Cell-Based Therapy for Type 1 Diabetes
DiaVacs, Inc. and Profil® Institute for Clinical Research, Inc. announced a strategic collaboration to conduct DiaVacs’ Phase Ib/IIa clinical trial. [Profil® Institute for Clinical Research, Inc.]
From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
Have we missed an important article or publication in Human Immunology News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.